Published in Liver Int on April 17, 2012
Porphyria cutanea tarda in the Basque Country: significance of HFE gene mutations and of external factors. Liver Int (2012) 1.40
The porphyrias: advances in diagnosis and treatment. Blood (2012) 1.34
Hepatitis C, stigma and cure. World J Gastroenterol (2013) 1.13
Dermatologic Extrahepatic Manifestations of Hepatitis C. J Clin Transl Hepatol (2015) 0.86
Hepatitis C- and HIV-induced porphyria cutanea tarda. Am J Case Rep (2014) 0.83
The Role of Iron and Iron Overload in Chronic Liver Disease. Med Sci Monit (2016) 0.78
Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload. Transfusion (2014) 0.75
Sun, iron, alcohol and intrinsic liver disease: a recipe for failure. BMJ Case Rep (2013) 0.75
Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir/sofosbuvir for hepatitis C. Clin J Gastroenterol (2017) 0.75
Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol (1994) 2.74
Iron and chronic viral hepatitis. Hepatology (1997) 2.18
Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology (2007) 2.09
Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology (2007) 1.94
Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol (2003) 1.86
Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol (2007) 1.85
Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology (2008) 1.81
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet (1997) 1.69
Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med (2007) 1.59
Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet (1993) 1.57
Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol (2000) 1.55
Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology (1992) 1.49
Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol (2009) 1.48
Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver (2002) 1.48
Hepatitis C and liver transplantation. J Hepatol (2001) 1.40
An overview of HCV molecular biology, replication and immune responses. Virol J (2011) 1.37
A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A (2007) 1.35
Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology (2006) 1.29
Iron in nonhemochromatotic liver disorders. Semin Liver Dis (2005) 1.25
An overview about hepatitis C: a devastating virus. Crit Rev Microbiol (2010) 1.23
Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood (2000) 1.14
Porphyria cutanea tarda--when skin meets liver. Best Pract Res Clin Gastroenterol (2010) 1.14
The role of iron in the pathophysiology and treatment of chronic hepatitis C. Can J Gastroenterol (2009) 1.12
Effects of visible light on the skin. Photochem Photobiol (2008) 1.10
Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology (2000) 1.09
Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology (1998) 1.06
Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci (2002) 1.06
The management of porphyria cutanea tarda. Clin Exp Dermatol (2001) 1.01
Hepatic porphyrias: diagnosis and management. Clin Liver Dis (2004) 1.00
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98
Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J Hepatol (2007) 0.97
Effects of phlebotomy on urinary porphyrin pattern and liver histology in patients with porphyria cutanea tarda. Am J Med Sci (1983) 0.97
Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol (2009) 0.96
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology (2011) 0.95
Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med (1986) 0.94
Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology (1998) 0.93
CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol (2000) 0.93
Genetic aspects of porphyria cutanea tarda. Semin Liver Dis (2007) 0.93
Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet (2009) 0.92
Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature. J Am Acad Dermatol (1999) 0.89
Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci (2007) 0.88
C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch (2001) 0.87
Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol (2005) 0.87
Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol (2009) 0.87
Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. N Engl J Med (1997) 0.86
Down-regulation of hepcidin in porphyria cutanea tarda. Blood (2008) 0.86
Guide to porphyrias. A historical and clinical perspective. Am J Clin Pathol (2003) 0.86
Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients. Liver Int (2004) 0.86
Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology (2003) 0.86
Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J Interferon Cytokine Res (2002) 0.85
Therapy of porphyria cutanea tarda. Expert Opin Pharmacother (2005) 0.85
The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol (1998) 0.85
Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: results from a randomized, controlled trial on 40 Japanese patients. Intern Med (2007) 0.85
Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. Australas J Dermatol (1988) 0.85
Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol (1995) 0.85
Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology (1997) 0.85
The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland. Clin Exp Dermatol (1996) 0.84
Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol (2005) 0.84
Retracted The porphyrias: pathophysiology. Intern Emerg Med (2010) 0.83
Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol (2005) 0.83
Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. World J Gastroenterol (2008) 0.83
Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection. Hepatology (1998) 0.82
Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol (2007) 0.82
CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med (2010) 0.82
C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria. Hepatology (1999) 0.81
Making sense of the porphyrias. Photodermatol Photoimmunol Photomed (2008) 0.81
Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher (2009) 0.81
The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population. J Am Acad Dermatol (2005) 0.81
Porphyrin metabolism in hepatitis C infection. Photodermatol Photoimmunol Photomed (1996) 0.81
Influence of hepatitis C virus (HCV) infection on porphyrin and iron metabolism in porphyria cutanea tarda (PCT) patients. Med Sci Monit (2001) 0.81
Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study. Acta Derm Venereol (2008) 0.80
Porphomethene inhibitor of uroporphyrinogen decarboxylase: analysis by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomed Chromatogr (2007) 0.80
A case-control histological study on the effects of phlebotomy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol (2011) 0.80
Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents. Bioorg Med Chem Lett (2010) 0.79
The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology (1997) 0.79
Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol (2003) 0.79
Hepatitis C and porphyria cutanea tarda. Cutis (1996) 0.79
Porphyria cutanea tarda, hepatitis C, alcoholism, and hemochromatosis: a case report and review of the literature. Cutis (2004) 0.79
Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE gene. A case-control study. Dermatology (2008) 0.78
Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology (1995) 0.78
The additive effects of hepatitis C infection and end-stage renal disease in porphyria cutanea tarda. Cutis (2006) 0.78
Patients with chronic hepatitis C may be more sensitive to iron hepatotoxicity than patients with HFE-hemochromatosis. Intern Med (2010) 0.78
Human herpesvirus-6 as an inducer of porphyria cutanea tarda: implications from a case. Transpl Infect Dis (2010) 0.77
The prevalence of hepatitis C in patients with porphyria cutanea tarda in Stockholm, Sweden. Acta Derm Venereol (2005) 0.77
Lesions on the hands, high aminotransferase levels. Cleve Clin J Med (2010) 0.77
Role of viral infection in porphyria cutanea tarda. Photodermatol Photoimmunol Photomed (1997) 0.77
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J (2006) 2.16
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology (2010) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology (2007) 1.59
T helper and B cell escape mutations within the HBc gene in patients with asymptomatic HBV infection: a study from the South-Eastern region of Iran. Clin Lab (2012) 1.52
MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology (2010) 1.38
Drug-induced liver injury associated with statins. Semin Liver Dis (2009) 1.36
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci (2013) 1.31
Iron in nonhemochromatotic liver disorders. Semin Liver Dis (2005) 1.25
Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAS. J Biol Chem (2004) 1.22
Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection. Hepatol Res (2007) 1.20
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
microRNAs: fad or future of liver disease. World J Gastroenterol (2011) 1.15
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol (2013) 1.10
HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. J Hepatol (2006) 1.10
The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. Biochim Biophys Acta (2012) 1.08
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology (2009) 1.08
Autoimmune hepatitis triggered by statins. J Clin Gastroenterol (2006) 1.06
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int (2008) 1.05
The diagnosis and management of erythropoietic protoporphyria. Gastroenterol Hepatol (N Y) (2008) 1.04
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology (2009) 1.03
Novel role of nuclear receptor Rev-erbα in hepatic stellate cell activation: potential therapeutic target for liver injury. Hepatology (2014) 1.02
Hepatic porphyrias: diagnosis and management. Clin Liver Dis (2004) 1.00
Fatal air and bile embolism after percutaneous liver biopsy and ERCP. Gastrointest Endosc (2005) 1.00
Lon peptidase 1 (LONP1)-dependent breakdown of mitochondrial 5-aminolevulinic acid synthase protein by heme in human liver cells. J Biol Chem (2011) 0.99
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol (2006) 0.97
CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. J Clin Virol (2009) 0.97
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology (2011) 0.95
The neuromediator glutamate, through specific substrate interactions, enhances mitochondrial ATP production and reactive oxygen species generation in nonsynaptic brain mitochondria. J Biol Chem (2009) 0.95
Hemochromatosis mutations in Iranians with hepatitis B virus infection. Clin Infect Dis (2004) 0.95
Structural analysis of heme proteins: implications for design and prediction. BMC Struct Biol (2011) 0.95
Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol (2013) 0.95
Intestinal expression of genes involved in iron absorption in humans. Am J Physiol Gastrointest Liver Physiol (2002) 0.93
Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor Bach1 and up-regulates HO-1. Biochim Biophys Acta (2008) 0.93
Genetic aspects of porphyria cutanea tarda. Semin Liver Dis (2007) 0.93
Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus. Liver Int (2010) 0.91
Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. Mol Cell Biochem (2008) 0.91
Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol (2002) 0.90
Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology (2009) 0.90
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Mapping of the chick heme oxygenase-1 proximal promoter for responsiveness to metalloporphyrins. Arch Biochem Biophys (2002) 0.88
Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane. Br J Pharmacol (2003) 0.88
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology (2010) 0.88
A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics (2010) 0.88
Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci (2007) 0.88
Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci (2013) 0.86
Hemochromatosis and porphyria. Semin Gastrointest Dis (2002) 0.86
Subcellular tissue proteomics of hepatocellular carcinoma for molecular signature discovery. J Proteome Res (2011) 0.86
Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes. PLoS One (2011) 0.84
Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. Clin Infect Dis (2005) 0.84
Identification of key elements that are responsible for heme-mediated induction of the avian heme oxygenase-1 gene. Biochim Biophys Acta (2004) 0.84
DNA methylation patterns in alcoholics and family controls. World J Gastrointest Oncol (2012) 0.84
Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochem J (2005) 0.84
Tissue-specific expression of ALA synthase-1 and heme oxygenase-1 and their expression in livers of rats chronically exposed to ethanol. FEBS Lett (2008) 0.83
Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J Proteomics (2010) 0.83
Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. World J Gastroenterol (2011) 0.83